We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Carnamedica has identified issues with third-party suppliers, which could result in microbiological contamination, particulate matter within the solution, and leakage of fluid.
Product defect recall alert for: Gallifen 200 mg/ml Suspension for Chickens and Pheasants (Vm 30282/4037), Pigfen 200 mg/ml Suspension for Pigs (Vm 30282/4038) by Huvepharma N.V
Upper Tribunal Tax and Chancery decision of Judge Rupert Jones and Member Peter Freeman of on 12 September 2022
Employment Tribunal decision.
The MHRA is providing an update on defects identified with Belzer solutions, manufactured by Carnamedica (UK Responsible Person Bridge to Life).
List of field safety notices (FSNs) from medical device manufacturers from 23 to 27 November 2020.
The CMA has imposed over £100 million in fines after Advanz inflated the price of thyroid tablets, causing the NHS and patients to lose out.
Latest developments in vaccines, vaccination policies and procedures for immunisation practitioners.
List of field safety notices (FSNs) from medical device manufacturers from 8 to 12 February 2021
Upper Tribunal Tax and Chancery Chamber decision of Judge Herrington and Tribunal Members Gary Bottriell and Mark White on 12 June 2023
Upper Tribunal Tax and Chancery decision of Mr Justice Mellor and Judge Thomas Scott on 28 January 2022
Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation.
September 2014 newsletter for immunisation practitioners, with the latest developments in vaccines, vaccination policies and procedures.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).